Turn Therapeutics' (TTRX) "Sell" Rating Reaffirmed at WBB Securities

Key Points

• WBB Securities reaffirmed its “sell” rating on Turn Therapeutics and set a $10 price target, implying 26.9% downside from the prior close.
• Analyst views remain mixed, but the overall consensus is “Hold” with an average price target of $9.00. Ratings include one strong buy, one buy, one hold, and two sells.
• Turn Therapeutics shares rose 7.8% to $13.68 in Monday trading, despite reporting a quarterly loss of $0.20 per share and carrying a high debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report)'s stock had its "sell" rating restated by stock analysts at WBB Securities in a research note issued on Monday, Benzinga reports. They presently have a $10.00 price target on the stock. WBB Securities' target price suggests a potential downside of 26.90% from the company's previous close.

TTRX has been the subject of several other research reports. Zacks Research raised shares of Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. Wall Street Zen upgraded Turn Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday. LADENBURG THALM/SH SH raised Turn Therapeutics to a "strong-buy" rating in a research report on Monday, July 20th. Finally, Weiss Ratings downgraded shares of Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $9.00.

Turn Therapeutics Stock Up 7.8%

Shares of NASDAQ:TTRX traded up $0.99 during midday trading on Monday, hitting $13.68. 46,670 shares of the company's stock traded hands, compared to its average volume of 55,069. The firm's fifty day moving average price is $9.71 and its two-hundred day moving average price is $6.28. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50. The company has a market cap of $407.53 million and a PE ratio of -47.57.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several hedge funds have recently made changes to their positions in TTRX. Hodges Capital Management Inc. acquired a new stake in Turn Therapeutics during the fourth quarter valued at approximately $39,000. LPL Financial LLC bought a new position in shares of Turn Therapeutics in the fourth quarter valued at $51,000. Bank of America Corp DE acquired a new stake in shares of Turn Therapeutics during the 2nd quarter valued at $103,000. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter worth $59,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Turn Therapeutics during the second quarter valued at $119,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.